Agios Pharmaceuticals Inc (AGIO) Exchange: NASDAQ

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases. Founded in 2007 and based in Cambridge, MA, Agios has a diverse team of more than 500 employees. Agios identified very early on the potential of targeting the metabolic pathways altered in cancer and inherited metabolic disorders, and focused its considerable energy and resources on researching the way in which metabolic deregulation could be affected in the body. From this mission statement the company has grown exponentially, experiencing a period of rapid growth which has led to a number of successful medications and a more robust drug pipeline. Agios has pushed the field of metabolic diseases and cancers forward with its groundbreaking research, allowing them to make consistent advances in their drug pipeline and offer innovative solutions to metabolic diseases and cancers. Agios has produced several successful drugs, including Tibsovo, Idhifa, and Enasidenib, with the latter recently gaining approval from the FDA in 2018. The success of these medications have allowed the company to establish itself as a leader in the field of metabolic-targeted therapeutics.